Anika Therapeutics, Inc.

  • Earnings Score
  • Moat Score
  • Market Cap $205.00M
  • PE -4
  • Debt -
  • Cash $55.63M
  • EV -
  • FCF -$2.33M

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings-$56.39M
EBIT-$2.76M
ROE-37%
ROA-1%
FCF-$2.33M
Equity$153.99M
Growth Stability-607%
PE-3.64
PB1.33
P/FCF-87.94
P/S1.71
Price/Cash0.27
Net Margins-47%
Gross Margins63%
Op. Margins-2%
Earnings CAGR-1%
Sales Growth YoY-103%
Sales Growth QoQ-103%
Sales CAGR6%
FCF CAGR-7%
Equity CAGR1%
Earnings Stability0.02
Earnings Growth YoY-65%
Earnings Growth QoQ-27%
Sales CAGR 5Y5%
FCF CAGR 5Y-12%
Equity CAGR 5Y-9%
Earnings CAGR 3Y-1%
Sales CAGR 3Y-1%
FCF CAGR 3Y-5%
Equity CAGR 3Y-19%
Market Cap$205.00M
Revenue$119.91M
Assets$202.74M
Cash$55.63M
Shares Outstanding14.42M
Earnings Score6%
Moat Score4%
Working Capital90.35M
Current Ratio4.88
Gross Profit$76.00M
Shares Growth 3y0%
Equity Growth QoQ-14%
Equity Growth YoY-27%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
Anika Therapeutics Inc is an orthopedic medicines company. It is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies. The company focuses on orthopedics, including osteoarthritis pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies. Geographically, it derives a majority of revenue from the United States.

SEC Filings

Direct access to Anika Therapeutics, Inc. (ANIK) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Anika Therapeutics, Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Anika Therapeutics, Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR -1%
Stability 2%
loading chart...

Anika Therapeutics, Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Anika Therapeutics, Inc..

= -$15M
012345678910TV
fcf-$2.3M-$2.2M-$2M-$1.9M-$1.8M-$1.6M-$1.5M-$1.4M-$1.3M-$1.2M-$1.1M-$11M
DCF-$2M-$1.7M-$1.4M-$1.2M-$1M-$860K-$729K-$617K-$523K-$443K-$4.4M
Value-$15M

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Net Margins33%31%28%18%24%-18%3%-10%-50%-47%-47%
ROA-21%16%8%11%-8%1%-5%-32%-1%-1%
ROE-15%12%7%9%-9%1%-5%-39%-37%-37%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024TTM
Debt over FCF----0------
Debt over Equity----0------
Growth Stability---59%98%-93%57%-607%---607%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201512/201612/201712/201812/201912/202012/202112/202212/202312/2024CAGR 5Y
Revenue YoY growth-11%10%-7%9%14%13%6%7%-28%5%
Earnings YoY growth-6%-2%-41%45%-188%-117%-459%456%-32%-
Equity YoY growth-6%18%0%9%-6%5%-1%-26%-27%-9%
FCF YoY growth--67%225%-5%13%-67%-72%-195%134%-68%-12%